A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
A Randomized, Open-Labeled, Multi-Center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Comparing With Morphine SR in Cancer Pain Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants with cancer pain and experiencing inadequate pain control on or approaching Step 2 of the World Health Organisation (WHO) analgesic ladder
- Participants with pain scores greater than and equal to 4 on the average in the last 24 hours
- Participants requiring or are expected to require not more than 540 milligram of oral morphine or morphine equivalent every 24 hours for the management of chronic cancer pain
- Participants who can reasonably be expected to achieve stable dose of opioid study medication for the duration of the trial
- Participants who can reasonably be expected to achieve stable dose of opioid study medication for the duration of the trial
Exclusion Criteria:
- Participants with pure or predominantly neuropathic pain or pain of unknown origin (where a mechanism or physical cause cannot be identified)
- Participants with acute pain or who have pain on movement
- Participants who have received a fentanyl patch within the last 5 days
- Participants intolerant or hypersensitive to hydromorphone or other opioids agonists (chemical substance capable of activating a receptor to induce a full or partial response)
- Participants with recent past history (within the previous 5 years) or current history of drug abuse or alcohol abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Hydromprphone Hydrochloride (HCl) OROS
Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase.
Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
|
Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase.
Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
|
|
ACTIVE_COMPARATOR: Morphine Sustain Release (SR)
Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days of titration phase.
Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
|
Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase.
Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief Pain Inventory (BPI) Questionnaire Item 3 "Worst Pain" Score at Day 14
Time Frame: Day 14
|
The BPI is a questionnaire designed to assess the severity and impact of pain on quality of life.
Total score ranges from 0=no pain to 10=extreme pain.
BPI Questionnaire Item 3 "Worst Pain" will be assessed using the BPI questionnaire, score ranges from 0 (no pain) to 10 (pain as bad as you can imagine).
|
Day 14
|
|
BPI Questionnaire Item 3 "Worst Pain" Score at Day 28
Time Frame: Day 28
|
The BPI is a questionnaire designed to assess the severity and impact of pain on quality of life.
Total score ranges from 0=no pain to 10=extreme pain.
BPI questionnaire Item 3 "Worst Pain" will be assessed using the BPI questionnaire, score ranges from 0 (no pain) to 10 (pain as bad as you can imagine).
|
Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BPI Questionnaire Item 6 "How Much Pain You Have Right Now" Score
Time Frame: Baseline, Day 14, Day 22 and Day 28
|
The BPI is a questionnaire designed to assess the severity and impact of pain on quality of life.
Total score ranges from 0=no pain to 10=extreme pain.
BPI questionnaire Item 6 "how much pain you have right now" will be assessed using the BPI questionnaire, score ranges from 0 (no pain) to 10 (pain as bad as you can imagine).
|
Baseline, Day 14, Day 22 and Day 28
|
|
BPI Questionnaire Item "Pain Intensity" Score
Time Frame: Baseline, Day 14, Day 22 and Day 28
|
The BPI is a questionnaire designed to assess the severity and impact of pain on quality of life.
Total score ranges from 0=no pain to 10=extreme pain.
BPI questionnaire Item "Pain Intensity" will be assessed using the BPI questionnaire, score ranges from 0 (no pain) to 10 (pain as bad as you can imagine).
|
Baseline, Day 14, Day 22 and Day 28
|
|
BPI Questionnaire Item "Pain Relief" Score
Time Frame: Baseline, Day 14, Day 22 and Day 28
|
The BPI is a questionnaire designed to assess the severity and impact of pain on quality of life.
Total score ranges from 0=no pain to 10=extreme pain.
BPI questionnaire Item "Pain Relief" will be assessed using the BPI questionnaire.
Pain relief was rated on a scale ranging from 0% (no relief) to 100% (complete relief).
|
Baseline, Day 14, Day 22 and Day 28
|
|
BPI Questionnaire Item "Pain Interference" Score
Time Frame: Baseline, Day 14, Day 22 and Day 28
|
The BPI is a questionnaire designed to assess the severity and impact of pain on quality of life.
Total score ranges from 0=no pain to 10=extreme pain.
BPI questionnaire Item "Pain Interference" will be assessed using the BPI questionnaire.
Pain interference of general activity, mood, walking ability, normal work, relationships with others, sleep, and enjoyment of life will be rated on a scale ranging from 0 (no interference) to 10 (complete interference).
|
Baseline, Day 14, Day 22 and Day 28
|
|
Patient's Global Assessment on Effectiveness
Time Frame: Day 14, Day 22 and Day 28
|
Participants will evaluate effectiveness by providing rating on the question "'what is your rating of the overall effectiveness of the study medication during the titration or maintenance phase" using 5-point scale ranging from 1 to 5, where 1=poor,.
2=fair, 3=good, 4=very good and 5=excellent.
|
Day 14, Day 22 and Day 28
|
|
Investigator's Global Assessment on Effectiveness
Time Frame: Day 14, Day 22 and Day 28
|
Investigator will evaluate effectiveness by providing rating on the question "'what is your rating of the overall effectiveness of the study medication during the titration or maintenance phase" using 5-point scale ranging from 1 to 5, where 1=poor,.
2=fair, 3=good, 4=very good and 5=excellent.
|
Day 14, Day 22 and Day 28
|
|
Number of Times the Pain Medication Required for Breakthrough Pain
Time Frame: Baseline up to Day 28
|
The requirement of breakthrough pain medication will be recorded by participants.
Morphine HCl, 10 mg, will be used as rescue medication for breakthrough pain.
|
Baseline up to Day 28
|
|
Mean Total Daily Dose (TDD) of Study Medication
Time Frame: Baseline up to day 28
|
Mean total daily dose of study medication taken during study will be recorded by participants.
|
Baseline up to day 28
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR015328
- 42801PAI3008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.